Radioactive iodine (iodine-131) therapy is indicated for the management of hyperfunctioning thyroid disease and thyroid cancer. It is classified as radioactive nuclear medicine and was first synthesized in 1941, and the FDA approved it in 1971 for its therapeutic use. Its action causes permanent destruction to the thyroid tissue by emitting radiation of two sorts, gamma and beta rays. Gamma radiation effects are more useful for diagnostic purposes, whereas beta radiation effects are therapeutic. Its action is dependant on the uptake of iodine from thyroid tissue and is ineffective in patients who have a hyperfunctioning disease without iodine uptake. Its indicated in patients who have a high surgical risk and decreased life expectancy, or patients who have failed to obtain a euthyroid state, or can not tolerate oral anti-thyroid agents. Radioactive iodine therapy may be administered as adjuvant therapy to surgery in patients with thyroid carcinoma and may be given four to six weeks of post-surgery.
FDA Approved use:
Radioactive iodine diagnostic use can differentiate between the different hyper or hypo functioning thyroid diseases. This differentiation occurs by measuring the uptake of radioactive iodine in the thyroid after 24-hours.
Iodine is a natural precursor for thyroid hormones triiodothyronine (T3) and thyroxine (T4) and is uptaken from the blood into the thyroid follicular cell by the sodium and iodide transporter. Similarly, radioactive iodine (RAI) exerts its effects once it is taken up by the follicular cells of the thyroid, emitting beta rays that further cause definitive local damage to the thyroid tissue.
Iodine-131 is available as:
Thyroid carcinoma dosage
Medications contradicted before therapy:
During radioactive iodine therapy, agents containing iodine can hinder its uptake from the transporter of thyroid cells, as iodine is a natural precursor for thyroid hormones. All patients should be on an iodine-free diet for seven days, and longer for patients receiving therapy for thyroid carcinoma. Although contraindicated, treatment with antithyroid agent methimazole (MTZ) may be initiated before radioactive iodine therapy in select patients who have severe hyperfunctioning thyroid disease or cardiac disease. Transient thyrotoxicosis may transpire shortly following radioactive iodine therapy due to the leakage of stored triiodothyronine (T3) and thyroxine (T4). Thionomide therapy may decrease any storage of thyroid hormones and ensure a euthyroid state to prevent possible complications of thyrotoxicosis. Methimazole is preferred over propylthiouracil(PTU) as it has a significant failure rate. If a patient receives ethionamide, the recommendation is to discontinue it three to five days prior to radioactive iodine therapy.
Adverse effects range from mild to severe, depending on the dose administered.
The recommendation for patients who have preexisting ophthalmopathy is for them also to have treatment with oral prednisone therapy to prevent exacerbations. Treatment can be started a few days after RAI therapy and should continue for 1 to 3 months. The damage to thyroid tissue during radioactive iodine therapy can release thyroid antigens, which may travel to the TSH autoantibodies located in the orbital, causing inflammatory and osmotic effects. Treatment with RAI may predispose patients to permanent hypothyroidism as it causes definitive destruction of thyroid tissue. Patients may require lifelong thyroxine therapy.
Radioactive iodine therapy (RAI) is contraindicated in the following:
The radioactive substance can pass through the placenta and may cause definitive thyroid damage and irreversible mental retardation to the developing fetus. Contraceptive use is a strong recommendation to females of childbearing age who are planning radioactive iodine therapy. A negative pregnancy test should be a consideration before initiating therapy as pregnancy and breastfeeding are absolute contraindications.
Monitoring and routine checkups are life long for patients following RAI therapy. Thyroid function tests are to be observed every 4-6 weeks for six months until the patient achieves a euthyroid or hypothyroid state. Free Thyroxine levels should be monitored routinely after treatment, as TSH levels can remain low for an extended duration despite the patient being clinically euthyroid. TFT can be monitored at six to twelve-month periods after achieving the treatment outcome. If treatment failure is suspected, and the patient is still in a hyperthyroid state six months post-therapy, the clinician may reconsider RAI retreatment.
Potassium iodide(KI) is effective in blocking radioactive iodine uptake in the thyroid and can be helpful during toxicity. RAI, once administered, has rapid absorption through the gastrointestinal tract and is spread to the thyroidal tissue via the bloodstream. RAI excretion is mainly within the kidneys. Patients with renal dysfunction are at risk of decreased clearance and increased levels of RAI and toxicity. Precautions should be advised to patients post-RAI therapy, as radiation may be harmful around others. Clinical staff must particularly take measures to avoid contact and exposure around women during pregnancy and children.
Radioactive iodine therapy(RAI) is a nuclear agent that is FDA-approved and indicated for hyperfunctioning thyroid disease and thyroid carcinoma. This agent's use should be under the management under the supervision of an interprofessional team, which includes an endocrinologist, a primary care physician, and a nurse. Thorough follow-up and communication between the primary care physician and specialists are vital to monitor free T4 and TSH levels to gauge the success or complications of treatment. Providers involved in the patients' direct care, such as nurses, should be familiar with the clinical signs and symptoms of treatment complications such as thyroid storm, ophthalmopathy, and transient hypothyroidism. Consultation with an ophthalmologist may be necessary for patients suffering from thyroid-associated orbitopathy.
Counseling and discontinuation of treatment are strongly advised during pregnancy, and a negative pregnancy test should be considered before therapy, as radioactive iodine can readily cross the placenta and be taken up by the fetus furthering causing irreversible damage. Select patients should be educated on pre-treatment if needed, and all patients should receive counsel about iodine restriction before therapy. Patients should receive clear instructions of radiation toxicity, and avoidance of household contacts, pregnant women, and children. The interprofessional team should also counsel patients on the adverse effects of therapy, and the early and late complications that may arise, and the severity of the complications.
|||Lee SL, Radioactive iodine therapy. Current opinion in endocrinology, diabetes, and obesity. 2012 Oct; [PubMed PMID: 22914564]|
|||Fard-Esfahani A,Emami-Ardekani A,Fallahi B,Fard-Esfahani P,Beiki D,Hassanzadeh-Rad A,Eftekhari M, Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma. Nuclear medicine communications. 2014 Aug; [PubMed PMID: 24751702]|
|||Sawin CT,Becker DV, Radioiodine and the treatment of hyperthyroidism: the early history. Thyroid : official journal of the American Thyroid Association. 1997 Apr; [PubMed PMID: 9133679]|
|||Wyszomirska A, Iodine-131 for therapy of thyroid diseases. Physical and biological basis. Nuclear medicine review. Central [PubMed PMID: 22936505]|
|||Limaiem F,Rehman A,Mazzoni T, Cancer, Papillary Thyroid Carcinoma (PTC) 2020 Jan; [PubMed PMID: 30725628]|
|||Pokhrel B,Bhusal K, Graves Disease 2020 Jan; [PubMed PMID: 28846288]|
|||Mathew P,Rawla P, Hyperthyroidism 2020 Jan; [PubMed PMID: 30725738]|
|||Mumtaz M,Lin LS,Hui KC,Mohd Khir AS, Radioiodine I-131 for the therapy of graves' disease. The Malaysian journal of medical sciences : MJMS. 2009 Jan; [PubMed PMID: 22589645]|
|||Ahad F,Ganie SA, Iodine, Iodine metabolism and Iodine deficiency disorders revisited. Indian journal of endocrinology and metabolism. 2010 Jan; [PubMed PMID: 21448409]|
|||Fox TJ,Anastasopoulou C, Graves Orbitopathy 2020 Jan; [PubMed PMID: 31751079]|
|||Marcocci C,Bartalena L,Tanda ML,Manetti L,Dell'Unto E,Mazzi B,Rocchi R,Barbesino G,Pinchera A, Graves' ophthalmopathy and 131I therapy. The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR). 1999 Dec; [PubMed PMID: 10731781]|
|||Reiners C,Schneider R, Potassium iodide (KI) to block the thyroid from exposure to I-131: current questions and answers to be discussed. Radiation and environmental biophysics. 2013 May; [PubMed PMID: 23475155]|
|||Becker DV,Zanzonico P, Potassium iodide for thyroid blockade in a reactor accident: administrative policies that govern its use. Thyroid : official journal of the American Thyroid Association. 1997 Apr; [PubMed PMID: 9133683]|
|||Bhat M,Mozzor M,Chugh S,Buddharaju V,Schwarcz M,Valiquette G, Dosing of radioactive iodine in end-stage renal disease patient with thyroid cancer. Endocrinology, diabetes [PubMed PMID: 29158901]|